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at 21 days after the placement in the rabbit iliac arteries (4). All
thrombi observed in this study were found at grade 0/1 sites; the
dominant pattern in ZES-implanted vessels in this study was grade
2/3 with less adhesion of thrombus. The ZES-implanted vessels
were associated with significantly less yellow plaques than SES.
Yellow plaque is also reduced by BMS placement, because both the
stent and the YP underneath the stent are covered by neointimal
development (5). The ZES is likely to have a “sealing” effect,
because ZES shows NIC more like that of BMS. These angio-
scopic findings suggest that arterial endothelial healing of ZES at
8 months after stent placement was more competent than SES. In
general, mean in-stent LL below 0.65 mm with stent platforms is
associated with TLR rates below 10% (6). Considering the risk
of stent thrombosis due to incomplete NIC, it is preferable for
DES to have sufficient neointimal volume no greater than LL of
0.65 mm.
Although the single-center, nonrandomized, matched-control,
and observational nature with a small sample size of this study
should be noted as a limitation, this study suggests that arterial
endothelial healing after stenting is more competent in ZES than
in SES. Optimal LL might be desirable for adequate arterial
endothelial healing after stenting.
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Letters to the Editor
Adjusting Clopidogrel Loading
Doses According to Vasodilator-
Stimulated Phosphoprotein Index:
On Time, Too Early, or Too Late?
We have read with great interest the report from Bonello et al. (1).
The authors have to be congratulated on publishing the first article
to show the clinical benefit of tailored antiplatelet therapy. We
would like to address a few comments to the authors.
The clinical evidence supporting the clinical predictive value of
the vasodilator-stimulated phosphoprotein (VASP) index is quite
low (2,3), and additional large-sample size studies may be required
to validate a definite cutoff. The authors used a cutoff of 50%,
previously associated with post-percutaneous coronary interven-
Figure 2 Coronary Angioscopic Images8 Months After SES and ZES Implantation
Left images (A, B) show a sirolimus-eluting stent (SES) (3.5  23 mm)
implanted case, and right images (C, D) show a zirolimus-eluting stent (ZES)
(3.5  23 mm) implanted case, both at the proximal portion of the right coro-
nary artery. (A, C) Angiograms at follow-up revealed no restenosis. (B) Angio-
scopic images of SES indicated grade 1 neointimal coverage throughout the
stent, with mural red thrombus adhesion observed at the proximal site of the
stent. Further, yellow plaques were observed underneath the stent (the entire
segment of the stent placed in the vascular wall was yellow). (D) In contrast,
ZES showed grade 3 neointimal coverage throughout the stent. Yellow plaques
existed in the distal native coronary artery adjacent to the distal end of the
stent. The vascular wall showed mild yellow saturation, while the stent portion
was covered with white-gray neointima with no yellow plaques observed (D,
bottom image). Open arrow  mural red thrombus; solid arrows  boundary
line of the neointimal coverage; GW  guidewire.
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tion (PCI) ischemic events, in a small sample size, single-center
study (2) with good negative predictive value but poor specificity.
Is it too early? Indeed, before adapting clopidogrel loading dose,
maybe we should define a consensual definition of nonresponse?
The difference observed between both groups is highly signifi-
cant, with no clinical events in the VASP-guided group. This
result could suggest that all post-PCI ischemic events are related to
nonresponse to clopidogrel, which is probably excessive. These
recurrences involve a complex and multifactorial process. The
recent TRITON–TIMI 38 (Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibition with
Prasugrel–Thrombolysis In Myocardial Infarction) study showed
that, even with a more potent P2Y12 inhibitor, the rate of
recurrent events significantly decreased but continued to exist (4).
The authors reported no excess of major bleeding in the
VASP-guided group and concluded that the strategy is safe.
However, the sample size of the present study does not allow for
such a definite conclusion. What would be the bleeding compli-
cations in a broad population of such strategy? Moreover, in the
whole population, 52% of the patients had VASP 50%, suggest-
ing the use of this strategy in more than one-half of the PCI
patients. Then, will the increased length in hospital stay be
acceptable for the public health system?
Is it too late? Indeed, in the near future, the alternative in
nonresponders might be to switch to alternative drugs such as
prasugrel. Then, the variability of response to clopidogrel would
become a resolved issue.
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Reply
We thank Dr. Cuisset and colleagues for their critical review of our
study (1). Many studies have suggested a stepwise relationship
between platelet reactivity (PR) and ischemic recurrences after
percutaneous coronary intervention (PCI), and the vasodilator-
stimulated phosphoprotein index has been used extensively used in
these trials. The threshold used to define low response in the
present study was chosen according to its clinical and biological
relevance (2–5). Further, this cut-off value exhibits a very high
negative predictive value and a low positive predictive value, which
illustrate the fact that, although ischemic recurrences are multifac-
torial, PR plays a key role.
Dr. Cuisset and colleagues seem to misunderstand available data
on PR and the hypothesis tested in our study. The interindividual
variability observed between patients in response to clopidogrel
means that the effect of a 2,400-mg loading dose for low
responders is inferior to that of 600 mg for good responders!
Indeed, available data support the fact that the response to the
drug, and not the dose, determines the outcome.
Finally, Dr. Cuisset and colleagues question the relevance of the
present study with regard to the future marketing of prasugrel. The
present trial is a landmark study demonstrating that PR is a
modifiable risk factor for recurrent ischemic events and therefore of
major interest not only for clopidogrel but for all other antiplatelet
therapies that will be developed. Further, consistent with our
results, researchers from the TRITON–TIMI 38 (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel–Thrombolysis In Myocardial Infarction)
study observed that greater PR inhibition, as achieved by prasugrel,
compared with standard clopidogrel therapy, resulted in lower
rates of ischemic events in patients undergoing PCI for acute
coronary syndromes (6). However, achieving 90% PR inhibition
with prasugrel resulted in a significant increase in major bleedings.
Accordingly, the authors do not support the use of prasugrel for
large subgroups of patients, including the elderly, those patients of
low weight, those patients with previous stroke, and those patients
undergoing elective PCI, which make up more than half of our
patients. In addition, finding a threshold of PR to decrease
ischemic events could be of great interest for the new P2Y12
ADP-receptor inhibitors to increase their risk/benefit ratio. Until
prasugrel is available, platelet monitoring of the response to
clopidogrel carries a potential clinical benefit for patients under-
going PCI. We believe that it is never too late to improve both our
practice and patient outcomes.
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